All three models agree that LLY’s Q1 earnings beat and raised 2026 guidance serve as a powerful catalyst for momentum repair and a re-rating toward $995-$1000. Technical indicators support this move, with two models highlighting price holding above key moving averages and one noting a bullish MACD reversal. For a 1-3 week swing, the optimal entry is a retest of the high-volume support zone between $916 and $923, leveraging the dominant GLP-1 market position to break through the $930.60 resistance level.
All three models identify the stock as overextended after an 8.8% rally, with two models specifically flagging an exhausted 30-minute RSI of 81 and immediate resistance at $930.60. Analysts warn of a high-probability mean reversion toward the $850 support level as post-earnings enthusiasm digests and growth stocks face sector rotation. Unique macro risks include an upcoming US GDP print and the fact that price remains below the daily SMA50, suggesting the current spike is a fadeable event rather than a sustainable breakout.
LLY has a fresh, dated catalyst after reporting Q1 results and raising 2026 outlook, which is helping the stock re-rate back above the 4h and daily short-term moving averages while healthcare breadth also confirms the move. For a 1-3 week swing, the cleaner long is not to chase the post-earnings spike into 4h resistance near $930.60, but to buy a retest into the high-volume area around $916-$918 and look for continuation as guidance momentum, positive analyst revisions, and momentum repair push price toward the upper daily range and a partial gap-fill zone near $995.
LLY looks like a shortable catalyst-repricing setup after an earnings-and-guidance surge pushed shares straight into 4-hour resistance at $930.60, with the 30-minute RSI stretched to 81 and price already above the upper intraday Bollinger band. For a 1-3 week swing, the cleaner path is mean reversion back toward the lower end of the value area and then support near the mid- $850s as post-earnings enthusiasm digests, especially with a high-impact US GDP macro event inside 24 hours that can interrupt a one-way chase. The stock is still below the daily SMA50, and without clean acceptance above resistance, upside continuation is less attractive than fading this overextended move on a retest entry.
Eli Lilly is positioned for upside following a strong Q1 earnings beat and raised 2026 guidance, driving renewed momentum. Price is holding above key moving averages on the 4-hour and daily charts, with MACD showing early signs of bullish reversal and RSI rising from neutral territory. The stock is consolidating just below resistance at $930.60, with high-volume nodes nearby at $916.75 and $923.06 providing structural support for continuation toward new highs.
Eli Lilly is extended at resistance after a sharp +8.8% rally into the $930.60 overhead barrier, with price now just 0.5% below key resistance. The move follows a Q1 earnings beat and guidance raise, but the technical structure shows exhaustion: RSI at 81 on the 30-minute, above both SMA20 and SMA50 across all timeframes, and volume trending down despite the price surge. This sets up a high-probability fade of the overextended move, with downside targeting the strong support at $850.51.
Eli Lilly's strong Q1 earnings and guidance raise, combined with its dominant position in the GLP-1 obesity market, support a long thesis. The recent price action, with a breakout above $900, indicates a potential trend reversal. With a technically sound stop below $850 and a target at $1000, this trade has a reasonable risk-reward profile.
LLY is due for a pullback after its recent earnings beat, with the stock price extending into resistance and showing signs of exhaustion. The healthcare sector is also experiencing a rotation out of growth stocks, which could further pressure LLY's price.